Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 35 (December 10), 2006: pp. 5576-5583
Published by the American Society of Clinical Oncology
DOI: 10.1200/JCO.2006.08.3774

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J. C.
Right arrow Articles by Childs, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J. C.
Right arrow Articles by Childs, R.

REVIEW ARTICLE

Immunotherapy for Renal Cell Cancer

James C. Yang, Richard Childs

From the Surgery Branch, Center for Cancer Research, National Cancer Institute; and the National Heart Lung and Blood Institute, Bethesda, MD

Address reprint requests to James C. Yang, National Cancer Institute, Room CCR/3-5952, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: jamesyang{at}mail.nih.gov

For eligible patients, the value of immunotherapy for metastatic clear-cell renal cancer is its curative potential, as demonstrated by long-term follow-up after interleukin-2. Advances in cellular therapies, manipulation of activating and inhibitory receptors on T cells and modification of allotransplantation regimens have all produced new tumor regressions in patients who did not respond to conventional interleukin-2 regimens. It is clear that renal cancer remains one of the most immunoresponsive of human malignancies and that advances in immune modulation are again translating into clinical responses for patients with this disease. As the array of biologic therapies for renal cancer expands with the approval of tyrosine kinase inhibitors, immunotherapy, the only modality that can cure widespread renal cancer, must not be overlooked.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
BloodHome page
C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood, June 1, 2008; 111(11): 5326 - 5333.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Wittnebel, S. Da Rocha, J. Giron-Michel, A. Jalil, P. Opolon, B. Escudier, P. Validire, K. Khawam, S. Chouaib, B. Azzarone, et al.
Membrane-Bound Interleukin (IL)-15 on Renal Tumor Cells Rescues Natural Killer Cells from IL-2 Starvation-Induced Apoptosis
Cancer Res., June 15, 2007; 67(12): 5594 - 5599.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. F. Bajorin, R. J. Motzer, and G. J. Bosl
Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research
J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online